drug · gene
lisocabtagene maraleucel
Phase 2updated 3mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Phase 2community read0 votes
Gene drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 8 investigational indications.
indications
indications
DLBCL
targets
B-lymphocyte antigen CD19
all catalysts(0)
nothing on the calendar yet
Trials studying lisocabtagene maraleucel
- phase2Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- phase3A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- phase1NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
- phase2Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- phase2Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
- phase2Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- phase2Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
- —Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
News(4)
- An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.biopharma_dive · 8d ago
- Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOsSanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.biopharma_dive · 11d ago
- Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdleSafety will be the key determinant of in vivo CAR T therapies, according to H.C. Wainwright’s Mitchel Kapoor, who noted that convenience and efficacy won’t be enough to impress investors in this sp…biospace · 16d ago
- Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely onTop-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.biospace · 20d ago
Data sources
last refreshed 32m ago
Found something off?
comments(0)
5-min edit window · permanent after that